Xencor Presents Data from Multiple Preclinical XmAb® Cytokine Programs at the American Association for Cancer Research (AACR) Annual Meeting 2022 Read more about Xencor Presents Data from Multiple Preclinical XmAb® Cytokine Programs at the American Association for Cancer Research (AACR) Annual Meeting 2022
Xencor to Present Preclinical Data from XmAb® Cytokine Programs at the American Association for Cancer Research (AACR) Annual Meeting 2022 Read more about Xencor to Present Preclinical Data from XmAb® Cytokine Programs at the American Association for Cancer Research (AACR) Annual Meeting 2022
Xencor Reports Fourth Quarter and Full Year 2021 Financial Results Read more about Xencor Reports Fourth Quarter and Full Year 2021 Financial Results
Xencor to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on February 23, 2022 Read more about Xencor to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on February 23, 2022
Xencor to Present at Upcoming Investor Conferences Read more about Xencor to Present at Upcoming Investor Conferences
Xencor Highlights 2022 Corporate Priorities and Portfolio Milestones Read more about Xencor Highlights 2022 Corporate Priorities and Portfolio Milestones
Xencor to Present at the H.C. Wainwright Bioconnect Virtual Conference Read more about Xencor to Present at the H.C. Wainwright Bioconnect Virtual Conference
Xencor Presents Data from Phase 1 Study of Plamotamab in B-cell Non-Hodgkin Lymphomas at the ASH Annual Meeting Read more about Xencor Presents Data from Phase 1 Study of Plamotamab in B-cell Non-Hodgkin Lymphomas at the ASH Annual Meeting
Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor Read more about Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor
